tbuckley/cabot-search huggingface dataset:
AB0942 ANTI-IL17 TREATMENT AND INCIDENCE OF INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS
Authors: R. Dos-Santos, I. Alcántara, D. Fernández Fernández, I. González Fernández, P. Castro-Santamaria, M. Sanchez-Wonenburger, A. Mata, J. L. Puga Guzmán, I. Álvarez, V. Busto, J. R. Maneiro, A. Souto Vilas, A. Mera Varela, E. Perez-Pampín
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> A warning about appearance or worsening of inflammatory bowel disease (IBD) during treatment with anti-IL17 agents has been launched by regulatory agencies in the last years. This caution is based on the relationship between bowel (IBD), joint (spondyloarthritis [SpA]) and skin (psoriasis [Ps]); regarding immune aspects. As well, anti-IL17 drugs have been proved ineffective in IBD treatment. <sup>[1,2]</sup> <h3>Objectives</h3> To analyze the incidence of IBD in patients with SpA or Ps treated with anti-IL17 drugs. <h3>Methods</h3> A systematic review about clinical trials has been performed using 4 databases (Medline, Embase, Web of Science, Cochrane Library). There were identified papers assessing the appearance of IBD in clinical trial's participants, previously diagnosed of Ps or SpA, treated with anti-IL17 drugs. A global incidence rate (IR), incidence rate ratio (IRR) and relative risks (RR) were estimated in this population, in paralell and crossover studies. Heterogeneity and risk of bias were also evaluated. <h3>Results</h3> 53 papers were finally selected for performing this meta-analysis. A global IR of IBD diagnosis in Ps/SpA patients under treatment with anti-IL17 was 0.3/100 patients-year (95%CI 0.24-0.37). An IRR of IBD diagnosis in Ps/SpA patients under treatment with anti-IL17 was 0.56 (95%CI 0.34-0.9, p&lt;0.01). A RR of IBD diagnosis in Ps/SpA patients under treatment with anti-IL17 in crossover trials was 0.73 (95%CI 0.27-1.99, p=0.54) (Figure 1). <h3>Conclusion</h3> We cannot afirm that anti-IL17 agents increase the global risk of IBD appearance in Ps or SpA patients. Anti-IL17 drugs may not be avoided in clinical practice concerning Ps and SpA patients, due to IBD prevention. <h3>References</h3> [1]McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis 2019 -09;78(9):1167-1178. [2]Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol 2019 -03;16(3):185-196. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0954 IMPACT OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH AS USING BIOLOGIC AGENTS
Authors: G. Sandal Uzun, İ. Y. Çakir, E. Bilgin, B. Farisogullari, G. Ayan, Z. Özsoy, M. Ekici, E. Unaldi, S. A. Germe, B. Firlatan, G. S. Kart Bayram, L. Kiliç, O. Karadag, A. Akdoğan, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, U. Kalyoncu
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Although renal involvement is an rare extra-articular involvement in patients with ankylosing spondylitis (AS), medications and accopamyning comorbidities may adversly affect renal functions [1]. <h3>Objectives</h3> To determine the frequency and impact of CKD in patients with AS using biologic disease modyfying anti-rheumatic drugs (bDMARDs). <h3>Methods</h3> Between 2005 and November 2021, 3207 patients diagnosed with AS according to the modified New York criteria were enrolled in the Hacettepe University biological database (HUR-BIO). The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guideline was used for the definition of CKD to evaluate the renal function of patients. Glomerular filtration rate (GFR) was calculated with the MDRD (modified Modification of Diet in Renal Disease) formula, taking into account the creatinine value, age and gender parameters of the patients [2]. CKD was detected in 39 (1,2%) patients. Age-sex matched 41 non-CKD AS patients were selected as the control group. Demographic and clinical characteristics and mortality rates of AS patients with and without CKD were compared. <h3>Results</h3> Of 39 AS-CKD patients, 25 (64.1%) had CKD before the initation of bDMARD and and 14 (35.8%) developed CKD during follow-up after treatment was started. Patients with AS-CKD had longer duration of symptoms and disease (Table 1). Comorbidities such as hypertension, coronary artery disease and amyloidosis were more prevalent in patients with AS-CKD. At a median follow-up of 2.48(0.1-20.1) years, mortality was observed in 11(28.2%) patients in the AS-CKD group, while no mortality was observed in the age-sex matched AS-nonCKD group (p&lt;0.001, Figure 1). The mortality rate in patients with AS-CKD was 12.6 per 1000 patient-years, and 4 (10.2%) of deaths were during the COVID-19 pandemia. <h3>Conclusion</h3> Both comorbid disease burden and mortality seem to be increased in patients with AS-CKD. Increased mortality was more pronounced during the COVID-19 pandemia. <h3>References</h3> [1]Coşkun, B.N., et al., <i>Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?</i> Eur J Rheumatol, 2022. <b>9</b>(2): p. 68-74. [2]Stevens, P.E. and A. Levin, <i>Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.</i> Ann Intern Med, 2013. <b>158</b>(11): p. 825-30. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1153 FATIGUE AND PSORIATIC ARTHRITIS: WHAT CHARACTERISTICS?
Authors: A. Ben Amou, S. Rahmouni, H. Tbini, K. Zouaoui, S. Rekik, S. Boussaid, H. Sahli, M. Elleuch
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Psoriatic arthritis (PsA) can cause an impairment of patients' quality of life. Fatigue is a common and often underestimated symptom in PsA. <h3>Objectives</h3> We aimed to assess the characteristics of fatigue in PsA. <h3>Methods</h3> This was a cross-sectional study including patients with PsA meeting CASPAR criteria. Socio-demographic, clinical and biological data were collected. The FACIT fatigue score (Functional Assessment of Chronic Illness Therapy) was calculated for all patients. It is a 13-item questionnaire evaluated on a five-point scale (4 = no fatigue to 0 = extreme fatigue), with scores from 0 to 52, the highest scores correspond to less fatigue [1]. <h3>Results</h3> There were 37 patients, the sex ratio M/F was 2.1. The mean age was 52.46±14.22 years, the mean age at disease onset was 41.32±14.69 years and the mean disease duration was 133.62±112.82 months. The mean BMI was 25.69±5.13 kg/m². The mean CRP was 31.63±37.95 mg/l. The patient global assessment (PGA) of the disease was 50.54±17.47. The mean DAS28-CRP score was 4.06±1.54. The mean BASDAI and ASDAS-CRP scores were 5.06±6.14 and 2.60±1.05, respectively. The mean DAPSA score was 38.31±35.05. The mean BASFI and HAQ were 4.91±2.59 and 1.30±0.93, respectively. The mean FACIT fatigue score was 16.11±11.99 [0-49]. It correlated with mean BMI value (r=0.444; p=0.044), age at disease onset (r=0.421; p=0.016), PGA (r=0.397; p=0.036), and HAQ (r=0.437; p=0.020). Patients with a BMI≥25 kg/m² had a higher FACIT fatigue score (19.94±13.20 vs. 11.00±8.12, p=0.049), In contrast, no correlation was identified with gender, age, smoking, disease duration, axial or peripheral involvement, extra-articular manifestations, high CRP levels, DAS28-CRP, BASDAI, ASDAS-CRP, DAPSA, BASFI, and hip involvement. <h3>Conclusion</h3> Fatigue is an important symptom in PsA and can be responsible for significant psychosocial impact and impairment of quality of life. Its assessment and management should be part of the overall management of PsA. <h3>Reference</h3> [1]Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003 Dec 16;1:79. doi: 10.1186/1477-7525-1-79. PMID: 14678568; PMCID: PMC317391. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1176 DIAGNOSTIC YIELD OF CT-GUIDED BIOPSY IN SUSPECTED INFECTIOUS SPONDYLODISCITIS
Authors: G. Mouna, D. Khalifa, H. Saghni, R. Fakhfakh, N. El Amri, K. Baccouche, E. Bouajina
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Infectious spondylodiscitis is a serious and morbid disease. It is often suspected after magnetic resonance (MR) imaging of the spine. Suspected spondylodiscitis requires further workup, in which computed tomography (CT)-guided needle biopsy plays a crucial role. <h3>Objectives</h3> The aim of this study was to examine the yield of CT-guided biopsy in patients with suspected infectious spondylodiscitis, and to identify factors associated with successful pathogen isolation. <h3>Methods</h3> This is a retrospective study involving infectious spondylodiscitis from January 2010 to december2021. All patients were identified with clinically and radiologically suspected infectious spondylodiscitis who underwent CT-guided biopsy of the vertebral lesion. Patient characteristics and clinical details were evaluated. Parameters were compared in patients with positive and negative microbiological and histologic results. <h3>Results</h3> A total of 42 patients (20 men, 22 women) was included. The mean age was 55.8 years (SD ± 16.7). The mean duration of symptoms was 60.2 days (SD ± 52.7). The final diagnosis was tuberculous spondylodiscitis in 15 patients (23.8%), brucellosis spondylodiscitis in 12 patients (28.6%) and pyogenic spondylodiscitis in 15 patients (47.6%). CT-guided biopsy has a diagnostic yield of 44.8% (13/42). Biopsy was contributory in identifying 8/13 patients (58%) with tuberculous spondylodiscitis, and 5/13 patients (42%) with pyogenic spondylodiscitis. Histological examination was the most sensitive diagnostic modality. The factors associated with successful microbe isolation was duration of symptoms (p=0.01) and not exposed to pre-biopsy antibiotics (p=0.02). <h3>Conclusion</h3> The CT-guided biopsy, as a diagnostic procedure for infectious spondylodiscitis, has a reasonably high diagnostic yield in this disease. A higher yield was identified in patients who has long duration of symptoms and not exposed to pre-biopsy antibiotics. <h3>References</h3> [1]Kasalak Ö, Wouthuyzen-Bakker M, Adams HJA, Overbosch J, Dierckx RAJO, Jutte PC, Kwee TC. CT-guided biopsy in suspected spondylodiscitis: microbiological yield, impact on antimicrobial treatment, and relationship with outcome. Skeletal Radiol. 2018 Oct;47(10):1383-1391. [2]Foreman SC, Schwaiger BJ, Gempt J, Jungmann PM, Kehl V, Delbridge C, Wantia N, Zimmer C, Kirschke JS. MR and CT Imaging to Optimize CT-Guided Biopsies in Suspected Spondylodiscitis. World Neurosurg. 2017 Mar;99:726-734.e7. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1168 AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS: WHAT PARTICULARITIES?
Authors: H. Bara, A. Rafi, F. E. Bennani, A. Mougui, I. El Bouchti
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Psoriatic arthritis (PsA) is a chronic inflammatory rheumatism belonging to the spondyloarthritis. It is characterised by a heterogeneous clinical presentation. <h3>Objectives</h3> The aim of our work is to evaluate the characteristics of axial involvement in RPso. <h3>Methods</h3> Retrospective study of 86 patients followed for RPso in the rheumatology department over a period of 7 years from 2014 to 2021. The patients were divided into 2 groups: group 1 (RPso with axial involvement) and group 2 (RPso without axial involvement). <h3>Results</h3> Our study involved a population of 86 patients with RPso, the average age was 44.7 years with a female predominance (58.6%), 16.1% of the patients were diabetics, 9.3% were hypertensive, 9.3% were smokers and 2.4% had a history of psoriasis in the family. Concerning the clinical manifestations, 95.3% of patients had polyarthralgia, 73.3% had polyarthritis, 29.4% had deformities and 86% had axial involvement. The bivariate analysis allowed us to identify the results summarised in the following Table 1: <h3>Conclusion</h3> Axial involvement in our study was present in 86 % of the patients and was associated with a long. duration of evolution and a statistically significant higher average CRP. <h3>Reference</h3> [1]Mease, P. J., Palmer, J. B., Liu, M., Kavanaugh, A., Pandurengan, R., Ritchlin, C. T.,... &amp; Greenberg, J. D. (2018). Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>The Journal of rheumatology</i>, <i>45</i>(10), 1389-1396. <b>Table 1.</b> Univariate analysis to the characteristics of the 2 groups. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0965 EXTRA-AXIAL MANIFESTATIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: THE COURSE AND RESPONSE TO THERAPEUTIC AGENTS
Authors: A. Yilmaz, E. Bektaş, A. Canik, B. Artim-Esen, M. Inanc, A. Gül, Y. Yalçinkaya
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Axial spondyloarthritis (axSpA) is a chronic inflammatory disease involving the axial skeleton and commonly include some coexisting extra-axial manifestations (EAMs) <sup>[1]</sup> which may have an influence on prognosis and treatment decisions <sup>[2]</sup>. <h3>Objectives</h3> We aim to show the characteristics of EAMs in patients with axSpA and to assess the progress under different therapeutic agents. <h3>Methods</h3> In this retrospective cohort study; medical records of all patients with axSpA who fulfilled ASAS classification criteria and were followed up between 1980 to 2022 at our tertiary referral outpatient clinic were screened. The data of 201 (59.7% males) patients who had sacroiliitis (by using X-Ray or MRI) and coexisted EAMs was recorded into a pre-defined protocol. Demographics and progress of EAMs under different therapeutic agents were analysed. <h3>Results</h3> The mean age and duration of follow-up period were 34 years (IQR 25-43) and 144 months (IQR 84-213). Prevalence of family history and HLAB27 were 30.6% (38/124) and 77.4% (65/84). Non-radiographic sacroiliitis was observed in 21.9%. Peripheral arthritis (60%) was the most common EAM and followed by uveitis (46%), IBD (17%), psoriasis (14%), enthesitis (13%) and dactylitis (5%). Demographics and treatment details are shown in <i>Table 1</i> and <i>Figure 1</i>. Approximately, half of the patients were treatment naive at onset of each EAMs. Anterior uveitis and psoriasis were frequently occured despite using bDMARDs (31% and 39%). Fifty nine percentage of the patients with psoriasis and one third of patients with uveitis and dactylitis required a switch to bDMARDs. <h3>Conclusion</h3> In patients with axSpA, some of EAMs required treatment switches and relapses occured despite treatment optimization. Determining appropriate and efficaceous treatment algorithms according to presence of EAMs should be one of the main goals of axSpA management strategies. <h3>References</h3> [1]Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021 Dec; 80: 1511-21. [2]Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/ Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 2019;71:1285-99. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1008 TIME, DURATION AND ORDER OF APPEARANCE OF EXTRA-ARTICULAR MANIFESTATIONS IN SPONDYLARTHRITIS: CLINICAL RISK FACTORS
Authors: C. Marco Pascual, A. García-Alija, H. S. Park, A. Laiz, P. Moya Alvarado, A. Casals Urquiza, C. Diaz-Torne, H. Codes, L. Sainz Comas, S. Ros, S. P. Fernandez-Sanchez, I. Castellví, B. Magallares, A. Garcia-Gullien, J. L. Tandaipan, C. Pitarch Grau, A. M. Millán Arciniegas, H. Corominas
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Little is known about the chronologic order of appearance of extra-articular symptoms and spondylarthritis (SpA) symptoms and its effect in disease progression. Most information is based on population-based registries or big data that may lack precision. <h3>Objectives</h3> To describe duration, time until diagnosis and order of appearance of the articular and extra-articular (psoriasis, uveitis, or inflammatory bowel disease) symptoms. To evaluate factors associated with time from extra-articular symptoms onset until appearance of SpA symptoms. <h3>Methods</h3> A retrospective cohort study was conducted. Inclusion criteria were patients that met ASAS criteria visited at the SpA clinic between July – October 2022. Other autoimmune rheumatic diseases were excluded. Data were collected previously reviewing patient records available from the electronic and paper database of the hospital. Additional information was retrieved by the shared medical history database of the Catalan Institute of Health which attends the 99.2% of the population. Missing data were collected prospectively by patient interview. Univariate linear regression was conducted to study association. <h3>Results</h3> From 91 patients 54 (59.3%) were male and mean age was 63.9 (SD 14.3). There were 46 (50.5%) patients with exclusively peripheral SpA and 17 (16.5%) exclusively axial SpA. History of extraarticular symptoms were observed in 69 (76.6%) of the patients and 33 (37.1%) were HLA-B27 positive. In 49 (54.8%) patients extra-articular symptoms appeared before SpA. The median disease duration since SpA diagnosis was 11 year (IQR 14). Median time for SpA diagnosis since articular symptoms onset was 2 years (IQR 8). The median time from the extra-articular symptoms until the appearance of articular symptoms was 2 years (IQR 30). The associations of SpA features and time since first extra-articular symptoms until articular symptoms appearance is detailed in table 1. HLA-B27 positivity and axial disease showed a negative linear association while peripheral disease showed a positive linear association. <h3>Conclusion</h3> Most patients presented extra-articular manifestation before articular symptoms onset. The median delay since first articular symptoms until SpA diagnosis was 2 years. Longer time between extra-articular manifestation and articular symptoms was liniarly associated with peripheral disease. Axial disease and HLA-B27 were linearly associated with shorter time between the two symptoms. <h3>Reference</h3> [1]Rheumatol 2021;60(6):2725-2734. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0991 RADIOGRAPHIC EVALUATION OF FOOT SPURS IN SPONDYLOARTHRITIS
Authors: H. H. Gezer, O. Pehlivan, M. T. Duruöz
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Although bone spurs are frequently seen in non-inflammatory diseases, they can also be seen with inflammation of the enthesis areas, especially in spondyloarthritis (SpA). <h3>Objectives</h3> To investigate the radiological evaluation of foot spurs in SpA and compare the characteristics between the SpA and degenerative diseases. <h3>Methods</h3> This ongoing study included 168 (124 women) patients with radiographic plantar or achilles spur. Age, disease duration, and body mass indexes were recorded. Patients were categorized with inflammatory [non-radiographic SpA (nr-AxSpA), radiographic SpA (r-AxSpA), psoriatic arthritis (PsA), and other) and non-inflammatory [osteoarthritis (OA) and diffuse idiopathic skeletal hyperostosis (DISH)]. Foot radiographs of the plantar region, achilles, and other regions (anterior ankle, posterior ankle, and tarsal bones) were examined for the spurs. The spur caharacteristics were evaluated. Three measurements were taken from each radiograph: plantar spur base, mid-segment, and length in millimeters. The differences were compared between SpA patients and controls. <h3>Results</h3> The mean age of the patients was 50.8 (SD:11.3) years, and the mean disease duration was 55.1 (SD:55.8) months. One hundred twenthy eight (76.2%) were in the inflammatory group [PsA (n=56), r-axSpA (n=30), nr-axSpA (n=27), other SpA (n=14)], while 40 (23.8%) were in the non-inflammatory [OA (n=35), DISH (n=5)] group. Plantar spur base, midsegment, and length were higher in the non-inflammatory group than in the inflammatory group (p&lt;0.05). Fluffy structure and erosion in the plantar spur were more common in the inflammatory group (p&lt;0.05). The characteristics of the spurs were not different between diseases in the inflammatory group (p&gt;0.05). Plantar spur lengths in the PsA patients were significantly higher than in the non-PsA SpA group (p=0.028 and 0.003); other spur features between groups were not different (p&gt;0.05). <h3>Conclusion</h3> Spurs are smaller and erosion and fluffy appearance are more common in SpA patients compared to non-inflammatory conditions. Spur characteristics are not different among SpA group diseases; only the plantar spur lengths were higher in patients with PsA. Although calcaneal and achilles spurs are frequently evaluated in clinical practice, approximately half of the patients also have spurs in the tarsal bone. <h3>Reference</h3> [1]Gladman, D. D et al. (2014). Radiological characteristics of the calcaneal spurs in psoriatic arthritis. Clinical and experimental rheumatology, 32,401–403. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1015 FETUIN-A: A NEW BIOMARKER OF BONE DAMAGE IN EARLY AXIAL SPONDYLARTHRITIS. RESULTS OF AN INTERIM ANALYSIS OF THE SPACE STUDY
Authors: M. Favero, F. Ometto, E. Belluzzi, G. Cozzi, L. Scagnellato, F. Oliviero, P. Ruggieri, M. Lorenzin, A. Doria, R. Ramonda
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Fetuin-A serum levels have been variably associated with radiological damage in axial spondyloarthritis (axSpA). <h3>Objectives</h3> The aim of this study was to evaluate the association of fetuin-A with the presence of radiographical sacroiliitis and syndesmophytes in early axSpA and to identify predictors of radiological damage in the sacroiliac joints (SIJ) after 24 months. <h3>Methods</h3> Patients with axSpA in the Italian cohort of the SpondyloArthritis-Caught-Early (SPACE) study were included. Physical examinations, laboratory tests (including fetuin-A), SIJ and spinal plain radiographs and MRIs at T0 (diagnosis) and at T24 were considered. Radiological damage in the SIJ was defined according to modified New York (mNY) criteria. <h3>Results</h3> Fifty-seven patients were included (41.2% males, average chronic back pain duration of 13.2±6 months). Fetuin-A levels were lower in patients with radiological sacroiliitis compared to those without at T0 (205.7±59.7 vs 249.7±50.4 μg/mL, respectively, p &lt;0.001) and at T24 (222.3±51.5vs 272.3±91.6 μg/mL, p=0.03) (Table 1). T0 fetuin-A levels significantly correlated with mNY score at T0 and at T24, and T24 fetuin-A levels with mNY at T24 (Figure 1). At T0, fetuin-A levels were significantly higher in non-smokers, in patients with heel enthesitis and in those with a family history of axSpA; at T24 levels were higher in females, in patients with higher ESR/CRP at T0 and in those with radiological sacroiliitis at T0 (Table 1). Following multivariable analysis, fetuin-A at T0 resulted negatively associated with the likelihood of radiological sacroiliitis (OR=0.9 per 10-unit increase (95%CI 0.8, 0.999), p=0.048); but not with syndesmophytes. Fetuin-A at T0 and T24 were associated with mNY at T0 (β -0.5, p&lt;0.001) and at T24 (β -0.3, p&lt;0.001), respectively; T0 fetuin-A levels did not achieve statistical significance in predicting mNY at T24 (β -0.9, p&lt;0.001). <h3>Conclusion</h3> Fetuin-A levels were negatively associated with radiological damage of the SIJ, but not of the spine, in early axSpA and after 2 years of follow-up. Fetuin-A levels may serve as biomarker to identify patients with a more severe disease and early structural damage. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.